Research programme: protease-activated receptor-2 inhibitor - NeoPharm
Latest Information Update: 14 Jul 2016
At a glance
- Originator NeoPharm Co
- Class Skin disorder therapies
- Mechanism of Action PAR 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Skin disorders
Most Recent Events
- 14 Jul 2016 Early research is ongoing in South Korea